Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
about
Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung CancerCIViC databaseERCC1 and XRCC1 as biomarkers for lung and head and neck cancerTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerNucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies.Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients.Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Cis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium.Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.Polymorphisms in ERCC1 and XPF genes and risk of gastric cancer in an eastern Chinese populationAtaxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysisXRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjectsGenetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.Overview of electrochemical DNA biosensors: new approaches to detect the expression of lifePharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin.Pharmacogenomics of platinum-based chemotherapy in NSCLCPredictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studiesExpression of XPG protein in human normal and tumor tissues.Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based ChemotherapyHigh XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.XPG Gene Polymorphisms Contribute to Colorectal Cancer Susceptibility: A Two-Stage Case-Control Study.The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.Association between genetic variants in the XPG gene and gastric cancer risk in a Southern Chinese population.Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysisGermline genetic markers for urinary bladder cancer risk, prognosis and treatment response.Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.The role of beclin-1 expression in patients with gastric cancer: a meta-analysis.Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations.What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.Platinum pathway.Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer.
P2860
Q26743378-535E2A21-A151-4ED2-8CBB-22721CB2B4B9Q27612411-D5698E2B-0CF6-4CC7-A245-EA69CFED01C4Q28391646-D97EFEE0-6B3A-4BC7-80F5-80C61702A705Q28396304-FF7C79B9-A4CC-4F29-BC3F-245D29B2575CQ33733507-C8237BBB-A33B-4218-ADFC-636137FA0169Q33752840-3A08F8E4-8F4A-4FE1-8877-48EB8F81D684Q33912148-5678756B-0F96-478B-B526-6801D8A6F484Q33947765-B5691ED0-374B-4CFF-B4E3-A8592B7B95C1Q34160411-1A13DE09-BEFB-4860-A905-CD195613D6A1Q34325669-BD657327-7658-4650-99F0-07D4117F87B1Q34482197-0B2AF425-34AE-47F9-AC43-A6795B3896F4Q34603025-5820F3C2-15FD-454E-8742-01FCB2EB7C96Q34934491-FC0F97F1-9F61-4E32-B3E7-5E9154EE8C8DQ35173399-B637B49A-FD7D-4AF2-94A1-91C57C767366Q35196480-B13ACF71-C46D-442C-B0D6-4ECEEF3ADF50Q35948439-6AE4A6E6-F253-4632-8AE2-0DA7CD486199Q36046527-90F1FB94-D0A2-459E-9016-CE58B6C32F4DQ36158678-CE531EA2-4172-4B19-89F6-A3F502D56D3CQ36301463-A728A215-1790-466D-A3E0-17D4A71168CDQ36375374-196FF4A3-63A9-46A3-946B-E58EB8FB115FQ36386267-F1919BD1-C2FC-42BE-BAEB-A186E0E8B51FQ36529982-45E24C0E-7B94-480B-BED7-29CB7B455D56Q36993563-35268E6B-1D9D-4DDB-B1FF-F715DEB301DFQ37050088-EF57A8FD-9C33-43B0-BB4D-258ACFE30D2DQ37290575-E607559B-9170-498F-9FFD-2E3421B34CCBQ37321149-FE225032-5709-44F1-BF5C-2709309924D8Q37610189-00EB8075-5BB2-42A1-9628-841F0B2B969FQ37688309-D0D521C8-0352-4511-8F8F-7BACEA717EECQ37797468-EC4F92CB-C5DC-43B3-918C-7A2832BBC984Q38276429-FA60037E-6C39-44D7-9D6F-F2B43215F664Q38372127-71423E8F-B925-4338-A271-3A28AE3AD702Q38405705-B37E672D-F6D8-4D7C-A0FF-DB33CC6A5119Q38909984-6AB42A1D-9EC0-4393-AB09-071DC75DDDCFQ39229428-5FD6AC7B-8E4B-4103-9662-FB91E1A500A4Q39389074-6ACBF72C-DD53-4FF7-97B6-4C6ABA0FA7F0Q40735558-285B3F2A-B6A9-4CE9-9EE5-D052B05E62B9Q41117085-168407D1-0721-4302-B8BE-082BE4D17C3FQ41791551-1B102323-B5B8-493D-BFE6-4B49940B129AQ43833692-0D111404-113A-42B3-BF51-428DB71C5814Q44386340-C92DE9A1-53B9-446D-914D-58F98C851CF7
P2860
Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@ast
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@en
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@nl
type
label
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@ast
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@en
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@nl
prefLabel
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@ast
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@en
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@nl
P2093
P3181
P1433
P1476
Polymorphisms in XRCC1 and XPG ...... all cell lung cancer patients.
@en
P2093
Cao YuanDong
Chen Baoan
Cheng Hongyan
Feng Jifeng
Ji Jiazhong
Qin Shukui
P3181
P356
10.1016/J.LUNGCAN.2008.11.014
P577
2009-08-01T00:00:00Z